Enterprise Value
8.075B
Cash
475.6M
Avg Qtr Burn
-24.56M
Short % of Float
2.83%
Insider Ownership
2.34%
Institutional Own.
89.57%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Caplyta (Lumateperone) Details Bipolar depression, Mental health | Approved Quarterly sales | |
Caplyta (Lumateperone) Details Schizophrenia, Mental health | Approved Quarterly sales | |
Caplyta (Lumateperone) Details Mental health, Major depressive disorder | sNDA Submission | |
ITI-1284 (Lumateperone- Deuterated form) Details Alzheimer's disease | Phase 2 Data readout | |
Lenrispodun (ITI-214) (PDE1 inhibitor) Details Heart disease, Parkinson's disease | Phase 2 Data readout | |
Phase 1 Data readout | ||
ITI-333 Details Sleeping disorder, Bipolar depression, Opioid use disorder | Phase 1 Update | |
LAI (lumateperone long acting injection) Details Mental health, Schizophrenia, Major depressive disorder, Bipolar disease | Phase 1 Initiation |